Mark Platt assumes role as full-time President and CEO of Makana Therapeutics, a subsidiary of Recombinetics Makana and Recombinetics merged their operations in 2020 to facilitate the mission of helping solve the nation’s organ donor crisis by advancing xenotransplantation technology EAGAN, MN — January 18, 2022 — Recombinetics™ Inc., a [...]
Recombinetics Inc., a leading gene editing company with platform technology applied to biomedicine and animal agriculture, today announced a first-of-its-kind study to improve outcomes for patients diagnosed with a rare disease known as Tuberous Sclerosis Complex (TSC). Surrogen, a subsidiary of Recombinetics Inc., is focused on developing large animal models [...]
Eagan, MN, October 7, 2020–Recombinetics Inc., a leading gene editing company with platform technology in therapeutics development, today announced that it has merged its efforts with Makana Therapeutics, a leader in the field of xenotransplantation. Makana Therapeutics will become Recombinetics Inc.’s newest subsidiary and will be exclusively focused on solving [...]
Recombinetics today announced a collaborative research project with Mayo Clinic to advance Osteogenesis Imperfecta (OI) research by developing the first-ever swine models of OI. These models will help preclinical researchers better understand disease etiology and progression and provide a reliable preclinical model for establishing the safety and efficacy of new [...]
In honor of Glioblastoma Awareness Day (#GBMDay), Recombinetics today announced it has received a grant from the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), to fund the development of a novel genetically engineered swine model of glioblastoma, the most common and aggressive malignant primary brain [...]
Multiple healthy litters of naturally castrated piglets developed through precision breeding Male piglets are routinely castrated to improve the quality of meat for consumers by eliminating boar taint, an unpleasant odor, and unsavory taste. This practice is an animal well-being concern and is being banned in the European Union. In [...]
Project Aims to Introduce New Commercial Traits in Cattle Derived from Elite Genetic Lines Acceligen, a Recombinetics company, and Kheiron-Biotech, a Proinvesa Group company, are teaming up on a series of projects in Argentina that intends to produce multiple animal product lines to solve existing concerns in the cattle industries. [...]
Today, Recombinetics named Dr. Tad Sonstegard the first Chief Executive Officer of its wholly-owned subsidiary, Acceligen. Sonstegard will lead Acceligen’s efforts to raise capital and strategic partnerships for its products that genetically improve the health and well-being of livestock and aquaculture. With Acceligen now entering into significant commercial transactions, Sonstegard’s [...]
Recombinetics today announced a multi-project, collaborative research and development agreement with Mayo Clinic to advance capabilities to bioengineer human stem cells within swine models. The collaboration is focused on utilizing human stem cells to produce human tissue products in a surrogate pig for exo-transplantation back into humans. These regenerative stem [...]